Compare WAB & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAB | KVUE |
|---|---|---|
| Founded | 1869 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Specialty Chemicals |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.8B | 33.1B |
| IPO Year | 1995 | 2023 |
| Metric | WAB | KVUE |
|---|---|---|
| Price | $225.24 | $16.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $233.44 | $20.00 |
| AVG Volume (30 Days) | 757.2K | ★ 35.0M |
| Earning Date | 02-11-2026 | 02-05-2026 |
| Dividend Yield | 0.45% | ★ 4.93% |
| EPS Growth | 14.53 | ★ 35.31 |
| EPS | ★ 6.87 | 0.75 |
| Revenue | $10,785,000,000.00 | ★ $15,006,000,000.00 |
| Revenue This Year | $7.65 | N/A |
| Revenue Next Year | $7.98 | $2.81 |
| P/E Ratio | $32.65 | ★ $22.51 |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $151.81 | $14.02 |
| 52 Week High | $226.29 | $25.17 |
| Indicator | WAB | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 63.71 | 46.25 |
| Support Level | $213.11 | $16.56 |
| Resistance Level | $222.18 | $17.42 |
| Average True Range (ATR) | 3.82 | 0.23 |
| MACD | 0.19 | -0.07 |
| Stochastic Oscillator | 87.63 | 33.53 |
Westinghouse Air Brake Technologies Corp provides value-added, technology-based products and services for the freight rail and passenger transit industries and the mining, marine, and industrial markets. It provides its products and services through two main business segments: Freight and Transit. The company generates maximum revenue from the Freight segment, which manufactures new and modernized locomotives, provides aftermarket parts and services to existing locomotives, provides components to new and existing freight cars; builds new commuter locomotives; supplies rail control and infrastructure products, including electronics, positive train control equipment, signal design, and engineering services. Geographically, it generates a majority of its revenue from the United States.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.